# Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)

> **NCT00432237** · PHASE3 · COMPLETED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1703 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** MK0974 50 mg
- **DRUG:** MK0974 150 mg
- **DRUG:** MK0974 300 mg
- **DRUG:** Comparator: Placebo

## Key facts

- **NCT ID:** NCT00432237
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-03
- **Primary completion:** 2007-12
- **Final completion:** 2007-12
- **Target enrollment:** 1703 (ACTUAL)
- **Last updated:** 2015-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00432237

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00432237, "Safety and Efficacy Study of MK0974 in the Acute Migraine (0974-016)". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00432237. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*